For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

5th Jul 13

Pharmaxis Awarded Two ARC Linkage Grants for Fibrotic Research

Pharmaceutical company Pharmaxis (ASX:PXS) today announced that two of its research projects conducted in conjunction with the University of Sydney have been awarded funding under the Australian Research Council (ARC) Linkage Projects scheme.

Leading Australian renal physician Professor Carol Pollock is heading an investigation of the utility of Pharmaxis compound PXS-4728A in treating renal fibrosis, while in a separate project  Associate Professors Paul Young and Daniela Traini, and Dr Brian Oliver will work on developing  advanced inhalation technology to deliver  Pharmaxis’ compounds to underlying fibrotic cells in the lung.

The ARC Scheme will provide funding of $405,646 and $370,000 for the two projects respectively, over three years which will match expenditure by Pharmaxis.

Read full media release - pdf
20th Jun 13

European CF Clinical Trial in Paediatric Patients Begins

Pharmaceutical company Pharmaxis (ASX:PXS) today announced that it has enrolled the first subject into its European paediatric clinical trial evaluating Bronchitol® in cystic fibrosis.

The Phase 2 trial being conducted in Europe and Canada is a requirement of Bronchitol’s earlier European marketing approval for adults and if positive will form part of an application to extend this approval to treat children and adolescents in the EU with cystic fibrosis.

The trial is a 27 week randomised, double-blind crossover investigation of Bronchitol administered twice daily in approximately 160 patients with cystic fibrosis.  The trial is enrolling cystic fibrosis patients aged 6 to 17 years and will assess improvements in lung function, treatment induced sputum weight and safety.

Read full media release - pdf
18th Jun 13

Pharmaxis Presents New Analyses of Pooled Cystic Fibrosis Data at European Meeting

Pharmaceutical company Pharmaxis (ASX:PXS) has  presented  new analyses from the pooled data of its two large scale phase 3 studies in cystic fibrosis illustrating the longer term benefits for patients who respond to Bronchitol® and the product’s value to healthcare systems. The presentation has been made at this year’s European Cystic Fibrosis Society conference in Lisbon, Portugal where it was awarded “Best Poster”.

Read full media release - pdf